Astellas Pharma and Melbourne based Audax Biosciences announced on October 27 an exclusive option and license agreement for DAX-044, Audax’s lead immuno oncology candidate. Audax will receive upfront and potential option exercise payments totaling $285 million, and is eligible for up to $1.05 billion in development and commercial milestones plus tiered double digit royalties on worldwide net sales if the drug is approved, taking the headline value to about $1.34 billion before royalties.
DAX-044 is an immune targeted interleukin-12 antibody cytokine fusion built on Audax’s AVIKINE technology. It is designed to concentrate IL-12’s immune activating effect inside the tumor microenvironment while limiting the systemic toxicity that has historically constrained the class, and the companies say it has shown a potential best in class therapeutic index in preclinical studies. It remains in IND enabling work, with Audax funding development into a Phase 1 study expected to start in 2027.
The structure prices the risk honestly. Astellas pays for the option now and takes sole responsibility for global development, manufacturing and commercialization only if it exercises, subject to conditions including antitrust clearances. Audax keeps an option to co fund and co promote the drug in Australia and New Zealand, its home market. Astellas chief strategy officer Takahiko Iwaya said the pairing combines Audax’s science with Astellas’s development and commercialization capacity for cancers where effective immune stimulation remains an unmet challenge.
Context cuts both ways. Interest in engineered cytokines revived and then cooled earlier this decade as larger companies cut IL-12 programs after toxicity and dosing problems, and no IL-12 drug has reached the market. An option, rather than an acquisition, lets Astellas watch the Phase 1 safety data before committing the full sum, which is exactly the stage at which this target has failed before.